Dovato, based on Dolutegravir and Lamivudine, a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection, approved in European Union
The European Commission has granted Marketing Authorisation for Dovato ( Dolutegravir / Lamivudine ) for the treatment of HIV-1 infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or Lamivudine.
Marketing Authorisation for Dovato is supported by data from the landmark global GEMINI 1 and 2 studies that included more than 1,400 HIV-1 infected adults.
In these studies, Dolutegravir and Lamivudine have demonstrated non-inferior efficacy based on plasma HIV-1 RNA less than 50 copies per millilitre ( c/mL ), a standard measure of HIV control, at week 48 when compared to a three-drug regimen of Dolutegravir and two nucleoside reverse transcriptase inhibitors ( NRTIs ), Tenofovir disoproxil fumarate / Emtricitabine ( TDF/FTC ), in treatment-naïve, HIV-1 infected adults.
The safety results for Dolutegravir and Lamivudine seen in GEMINI 1 and 2 were consistent with the product labelling for Dolutegravir and Lamivudine.
Four patients ( 1% ) in both the Dolutegravir and Lamivudine, and the Dolutegravir and TDF/FTC, study arms experienced drug-related serious adverse events, and 15 patients ( 2% ) in the Dolutegravir and Lamivudine arm and 16 patients ( 2% ) in the Dolutegravir and TDF/FTC arm had adverse events that led to discontinuation.
The most common adverse reactions included headache, diarrhoea, nausea, insomnia, and fatigue.
No patient who experienced virologic failure in either treatment arm developed treatment-emergent resistance also up to week.
Dovato ( Dolutegravir 50 mg / Lamivudine 300 mg tablets ) is authorised in the EU for the treatment of HIV-1 infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or Lamivudine.
Dolutegravir / Lamivudine is a once-daily, single-pill, two-drug regimen that combines the integrase strand transfer inhibitor ( INSTI ) Dolutegravir ( Tivicay, 50 mg ) with the nucleoside analogue reverse transcriptase inhibitor ( NRTI ) Lamivudine ( Epivir, 300 mg ).
Like a Dolutegravir-based three-drug regimen, Dolutegravir / Lamivudine uses two drugs to inhibit the viral cycle at two different sites.
INSTIs, like Dolutegravir, inhibit HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells ( T-cells ).
This step is essential in the HIV replication cycle and is also responsible for establishing chronic infection.
Lamivudine is an NRTI that works by interfering with the conversion of viral ribonucleic acid ( RNA ) into deoxyribonucleic acid ( DNA ) which in turn stops the virus from multiplying.
With around 25,000 new HIV diagnoses in European Union every year, and the fact that HIV is considered a chronic condition which requires people living with HIV to remain on antiretroviral treatment for life, it is ever more important to provide innovative treatment options. ( Xagena )
Source: ViiV Healthcare, 2019
The nucleoside-modified messenger RNA in COVID-19 mRNA vaccine BNT162b2 is formulated in lipid nanoparticles, which enable delivery of the RNA...
Opdivo plus Yervoy for patients with hepatocellular carcinoma previously treated with Sorafenib, FDA approved
Opdivo ( Nivolumab ) 1 mg/kg plus Yervoy ( Ipilimumab ) 3 mg/kg ( injections for intravenous use ) was...
Initial preliminary findings from the Papa Giovanni XXIII Hospital sponsored SISCO ( Siltuximab In Serious COVID-19 ) Study, based on...
Adults and children with all genotypes of hepatitis C and compensated cirrhosis: Mavyret shortens duration of treatment to eight weeks, approved by FDA
The FDA ( U.S. Food and Drug Administration ) has expanded the approval of Mavyret ( Glecaprevir and Pibrentasvir )...
Results from the largest study of hepatitis B and C and HIV infection prevalence in cancer patients show an alarmingly...
FDA has approved Dovato, the first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment
The FDA ( U.S. Food and Drug Administration ) has approved Dovato ( Dolutegravir and Lamivudine ), as a complete...
The results of a study has shown that patients living with HIV and one of a variety of potentially deadly...
HIV-1 control with a 2-drug regimen of Dolutegravir plus Lamivudine in virally suppressed patients switching from a TAF-containing 3-drug regimen
Week 48 results from phase III TANGO study were announced. The TANGO study was conducted to assess whether adults living...
Biktarvy: Bictegravir, Emtricitabine, Tenofovir Alafenamide approved by FDA for treatment of HIV-1 infection
The FDA ( U.S. Food and Drug Administration ) has approved Biktarvy ( Bictegravir 50mg / Emtricitabine 200mg / Tenofovir...